Elucidating the Mechanisms of Hugan Buzure Granule in the Treatment of Liver Fibrosis via Network Pharmacology

Table 2

KEGG analysis of the overlapping targets (top 20).

Name of pathways	Count	FDR	Enriched genes
PI3K-AKT signaling pathway	24	4.47E − 10	BCL2, CHRM1, VEGFA, MYC, GSK3B, MDM2, EGFR, ERBB2, G6PC, MCL1, IL6, ERBB3, RELA, NOS3, IKBKG, CCND1, INS, IKBKB, CASP9, RAF1, IGF2, CHRM2, CCND2, PRKCA
MAPK signaling pathway	18	6.39E − 10	VEGFA, MYC, EGFR, ERBB2, RASA1, CASP3, ELK1, ERBB3, FOS, RELA, HSPB1, IKBKG, INS, IKBKB, MAPK8, RAF1, IGF2, PRKCA
HIF-1 signaling pathway	15	3.06E − 09	BCL2, VEGFA, EGFR, ERBB2, IL6, RELA, HIF1A, NOS3, INS, HK2, PRKCA, CFLAR, CASP8, ICAM1, VCAM1
NF-κB signaling pathway	11	3.09E − 09	BCL2, NFKBIA, RELA, IKBKG, IKBKB, CFLAR, PLAU, PARP1, ICAM1, VCAM1, EGFR
Hepatitis B	10	5.34E − 09	BCL2, MYC, NFKBIA, IL6, CASP3, ELK1, FOS, RELA, CYCS, BIRC5
Hepatitis C	10	4.98E − 08	MYC, GSK3B, EGFR, NFKBIA, CASP3, RELA, CYCS, IKBKG, CCND1, MAPK8
TNF signaling pathway	9	5.95E − 08	NFKBIA, IRF1, SELE, CASP7, IL6, CASP3, FOS, RELA, RB1
Hepatocellular carcinoma	9	3.38E − 07	GSTP1, NFE2L2, MYC, GSK3B, EGFR, ELK1, NQO1, CCND1, GSTM1
Ras signaling pathway	8	4.74E − 07	VEGFA, EGFR, RASA1, ELK1, RELA, RASSF1, IKBKG, INS
FoxO signaling pathway	7	5.18E − 07	CCNB1, MDM2, EGFR, G6PC, IL6, SLC2A4, CCND1
Insulin signaling pathway	7	1.19E − 06	INS, IKBKB, MAPK8, SREBF1, FASN, RAF1, HK2
Focal adhesion	7	1.42E − 06	BCL2, VEGFA, GSK3B, EGFR, ERBB2, ELK1, CAV1
Pancreatic cancer	6	1.76E − 06	VEGFA, EGFR, ERBB2, RELA, IKBKG, CCND1
IL-17 signaling pathway	6	2.50E − 06	GSK3B, NFKBIA, IL6, CASP3, FOS, RELA
VEGF signaling pathway	6	5.57E − 06	VEGFA, NOS3, HSPB1, CASP9, RAF1, PRKCA
p53 signaling pathway	5	9.47E − 06	CCNB1, BCL2, MDM2, IGFBP3, CASP3
Relaxin signaling pathway	5	2.26E − 05	VEGFA, EGFR, NFKBIA, COL3A1, FOS
Calcium signaling pathway	5	3.86E − 05	CHRM1, ADRA1A, EGFR, ERBB2, CHRM3
cAMP signaling pathway	4	6.05E − 05	FOS, RELA, MAPK8, ACOX1
AMPK signaling pathway	4	9.76E − 05	INS, SREBF1, FASN, PPARG